India Glycols Limited — Quarter ended 31 March 2026 (Audited) and year ended 31 March 2026 (Audited)
The following tables are extracted from the provided quarterly results document (₹ in crores unless otherwise stated).
| S.No. | Particulars | Quarter ended 31.03.2026 (Audited) Refer Note -3 | 31.12.2025 (Unaudited) | 31.03.2025 (Audited) Refer Note -3 | Year ended 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|---|---|---|---|
| 1 | Income from operations | |||||
| (a) Revenue from operations | 2,361.40 | 2,551.06 | 2,188.00 | 9,826.20 | 9,037.82 | |
| (b) Other income (Refer Note 8) | 39.20 | 0.74 | 1.59 | 43.51 | 14.55 | |
| Total income | 2,400.60 | 2,551.80 | 2,189.59 | 9,869.71 | 9,052.37 | |
| 2 | Expenses | |||||
| (a) Cost of materials consumed | 484.66 | 597.82 | 488.26 | 2,412.43 | 2,345.81 | |
| (b) Purchase of stock-in-trade | 40.25 | 40.81 | 30.59 | 188.46 | 111.80 | |
| (c) Changes in inventories of finished goods, Stock-in Trade and work-in-progress | 83.51 | 53.07 | 14.44 | 60.92 | (50.46) | |
| (d) Excise Duty | 1,383.66 | 1,448.70 | 1,325.43 | 5,615.22 | 5,270.69 | |
| (e) Employee benefits expense | 33.68 | 34.77 | 30.10 | 130.69 | 120.89 | |
| (f) Finance Costs | 26.41 | 46.81 | 44.53 | 167.18 | 164.37 | |
| (g) Depreciation and amortisation expense | 41.23 | 41.22 | 32.59 | 155.38 | 115.19 | |
| (h) Power and fuel | 87.69 | 105.79 | 75.44 | 400.50 | 361.88 | |
| (i) Other Expenses | 83.73 | 93.68 | 80.09 | 371.40 | 370.42 | |
| Total Expenses | 2,264.82 | 2,462.67 | 2,121.47 | 9,502.18 | 8,810.59 | |
| Profit Before Interest, Depreciation and Tax (EBIDTA) | 203.42 | 177.16 | 145.24 | 690.09 | 521.34 | |
| 3 | Profit / (Loss) from operations before exceptional items and tax (1-2) | 135.78 | 89.13 | 68.12 | 367.53 | 241.78 |
| 4 | Exceptional Items (Refer Note 7) | – | 0.83 | – | 0.83 | – |
| 5 | Profit / (Loss) before Tax (3-4) | 135.78 | 88.30 | 68.12 | 366.70 | 241.78 |
| 6 | Tax expense: | |||||
| (a) Current Tax | (9.13) | 12.91 | (0.19) | 21.07 | 17.14 | |
| (b) Deferred Tax | 34.63 | 10.13 | 17.96 | 63.30 | 44.26 | |
| 7 | Profit / (Loss) for the period (5-6) | 110.28 | 65.26 | 50.35 | 282.33 | 180.38 |
| 8 | Other Comprehensive Income | |||||
| A (i) Items that will not be reclassified to Profit or Loss | (1.52) | (0.25) | (1.31) | (2.27) | (1.16) | |
| (ii) Income tax relating to items that will not be reclassified to Profit or Loss | 0.38 | 0.06 | 0.33 | 0.57 | 0.29 | |
| B (i) Items that will be reclassified to Profit or Loss | – | – | – | – | – | |
| (ii) Income tax relating to items that will be reclassified to Profit or Loss | – | – | – | – | – | |
| Other Comprehensive Income (Net of Tax) | (1.14) | (0.19) | (0.98) | (1.70) | (0.87) | |
| 9 | Total comprehensive income / (loss) for the period (7+8) | 109.14 | 65.07 | 49.37 | 280.63 | 179.51 |
| 10 | Paid-up Equity Share Capital (Face value Rs. 5/- each) | 33.51 | 33.51 | 30.96 | 33.51 | 30.96 |
| 11 | Other Equity | 2,503.93 | 1,840.08 | |||
| 12 | Earning per equity share (face value of Rs 5/- each) Not annualised (In Rs.) (Refer Note 5 & 6) | |||||
| – Basic | 17.31 | 10.42 | 8.13 | 44.31 | 29.13 | |
| – Diluted | 17.31 | 10.42 | 8.13 | 44.31 | 29.13 |
| S.No. | Particulars | Quarter ended | Year ended | |||
|---|---|---|---|---|---|---|
| 31.03.2026 (Audited) | 31.12.2025 (Unaudited) | 31.03.2025 (Audited) | 31.03.2026 (Audited) | 31.03.2025 (Audited) | ||
| 1 | Segment Revenue | |||||
| – Bio-based Specialities and Performance Chemicals | 302.55 | 312.98 | 253.59 | 1,202.07 | 1,341.00 | |
| – Potable Spirits | 1,690.09 | 1,793.46 | 1,609.42 | 6,946.43 | 6,433.90 | |
| – Ennature Biopharma | 63.49 | 50.34 | 51.54 | 207.77 | 219.37 | |
| – Bio-Fuel | 305.27 | 394.28 | 273.45 | 1,469.93 | 1,043.55 | |
| Total | 2,361.40 | 2,551.06 | 2,188.00 | 9,826.20 | 9,037.82 | |
| 2 | Segment Results (Profit / (Loss) before Interest and Tax) | |||||
| – Bio-based Specialities and Performance Chemicals | 34.47 | 41.13 | 26.76 | 138.27 | 121.11 | |
| – Potable Spirits | 67.78 | 72.43 | 78.41 | 284.93 | 256.44 | |
| – Ennature Biopharma | 3.01 | 2.04 | 4.29 | 7.23 | 20.76 | |
| – Bio-Fuel | 30.21 | 32.99 | 15.90 | 115.23 | 56.68 | |
| Total | 135.47 | 148.59 | 125.36 | 545.66 | 454.99 | |
| Less/(Add) : | ||||||
| – Interest (Net) | 26.41 | 46.81 | 44.53 | 167.18 | 164.37 | |
| – Exceptional Items | – | 0.83 | – | 0.83 | – | |
| – Unallocated corporate expenses net of unallocable income | (26.72) | 12.65 | 12.71 | 10.95 | 48.84 | |
| Profit Before Tax | 135.78 | 88.30 | 68.12 | 366.70 | 241.78 | |
| 3 | Segment assets | |||||
| – Bio-based Specialities and Performance Chemicals | 3,595.99 | 3,371.41 | 3,543.43 | 3,595.99 | 3,543.43 | |
| – Potable Spirits | 596.60 | 614.74 | 579.23 | 596.60 | 579.23 | |
| – Ennature Biopharma | 426.42 | 431.21 | 441.01 | 426.42 | 441.01 | |
| – Bio-Fuel | 1,429.96 | 1,347.88 | 1,116.63 | 1,429.96 | 1,116.63 | |
| – Unallocated | 77.15 | 62.72 | 110.10 | 77.15 | 110.10 | |
| Total | 6,126.12 | 5,827.96 | 5,790.40 | 6,126.12 | 5,790.40 | |
| 4 | Segment liabilities | |||||
| – Bio-based Specialities and Performance Chemicals | 737.05 | 719.28 | 929.71 | 737.05 | 929.71 | |
| – Potable Spirits | 326.53 | 302.55 | 335.14 | 326.53 | 335.14 | |
| – Ennature Biopharma | 92.49 | 72.99 | 62.14 | 92.49 | 62.14 | |
| – Bio-Fuel | 92.27 | 74.40 | 89.81 | 92.27 | 89.81 | |
| – Unallocated | 2,340.34 | 2,180.17 | 2,502.56 | 2,340.34 | 2,502.56 | |
| Total | 3,588.68 | 3,349.39 | 3,919.36 | 3,588.68 | 3,919.36 |
| Particulars | Standalone Year ended | |
|---|---|---|
| 31.03.2026 (Audited) | 31.03.2025 (Audited) | |
| A. Cash Flow from Operating Activities | ||
| – Net Profit/(Loss) Before Tax | 366.70 | 241.78 |
| Adjustments For: | ||
| – Depreciation and amortisation expense | 155.38 | 115.19 |
| – (Profit)/Loss on Sale of Property, plant & equipment | (1.26) | (1.02) |
| – Net Unrealised Foreign Exchange Fluctuation (Gain) / Loss | 2.15 | 4.74 |
| – Govt Grant (Net) | (0.12) | (0.12) |
| – Dividend Income | (38.58) | – |
| – Provision No Longer Required Written Back | (2.28) | (20.47) |
| – Finance Costs | 168.33 | 165.74 |
| – Interest Income | (4.47) | (14.38) |
| Operating Profit/ (Loss) before Working Capital Changes | 645.85 | 491.46 |
| Adjustments For: | ||
| – (Increase)/Decrease in Trade & Other Receivables | 69.62 | 175.41 |
| – (Increase)/Decrease in Inventories | 280.81 | (65.10) |
| – Increase / (Decrease) in Trade & Other Payables | (203.69) | (219.57) |
| Cash Generated from / (Used in) Operations | 792.59 | 382.20 |
| – Income Tax Paid (Net) | (23.60) | (20.21) |
| Net Cash flow from / (Used in) Operating Activities | 768.99 | 361.99 |
| B. Cash Flow from Investing Activities | ||
| – Purchase of Property, plant & equipment | (823.48) | (760.47) |
| – Sale of Property, plant & equipment | 6.86 | 7.71 |
| – Interest received | 11.06 | 16.77 |
| – Dividend received | 38.58 | – |
| Net Cash flow from / (Used in) Investing Activities | (766.98) | (735.99) |
| C. Cash Flow from Financing Activities | ||
| – Proceeds from Borrowings | 438.31 | 860.27 |
| – Repayment of Borrowings | (664.12) | (376.75) |
| – Proceeds from issue of share capital | 466.99 | – |
| – Proceeds/(Payment) of lease liabilities | 24.88 | 60.14 |
| – Finance Costs paid | (168.21) | (165.31) |
| – Dividends Paid | (75.31) | (24.59) |
| Net Cash flow from / (Used in) Financing Activities | 22.54 | 353.76 |
| – Net Increase/(Decrease) in Cash & Cash Equivalents [A+B+C] | 24.55 | (20.24) |
| – Opening Cash & Cash Equivalents | 6.51 | 26.75 |
| – Closing Cash & Cash Equivalents | 31.06 | 6.51 |
| Particulars | Standalone As At | |
|---|---|---|
| 31.03.2026 (Audited) | 31.03.2025 (Audited) | |
| A. ASSETS | ||
| 1 Non-current Assets | ||
| (a) Property, Plant and Equipment | 4,445.21 | 3,736.18 |
| (b) Capital work-in-progress | 36.70 | 98.39 |
| (c) Investment Property | 1.72 | 1.75 |